ALKS · Alkermes plc · Stock research

've# ALKS — Alkermes plc

Current Thesis

The leg being bought is the conversion of a profitable legacy CNS commercial house — VIVITROL, ARISTADA, LYBALVI, now LUMRYZ — into an orexin-2 receptor (OX2R) sleep-medicine franchise built on alixorexton. Since the last note the two things that mattered both landed. Alkermes reported Q2 2026 revenue of $496.0M against a $457.8M consensus on 2026-07-28, with adjusted EBITDA $139.2M and adjusted EPS $0.00 versus a forecast $0.02 loss — but guided Q3 to $450–470M against a $472.8M consensus and merely affirmed FY2026 at $1.730–1.840B versus $1.812B consensus. Then on 2026-08-05 the FDA approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1, the first OX2R agonist ever cleared. The mechanism is no longer a hypothesis; it is a labelled, marketed drug. The stock did not make a new high on that news: the 2026-08-07 close was $49.17, 11.0% below the $55.22 52-week high, with RSI(14) at 39.3 after spending June in the 80s.

Life-cycle read: MATURING. Dating it — the discovery phase ended with Vibrance-2 on 2026-06-17; the sell-side caught up between 2026-06-09 and 2026-07-29 (RBC $56, TD Cowen $50, Needham $54→$61→$62, Piper Sandler $65 on 07-28, JPMorgan Neutral $61 and Baird $58 on 07-29); and the class's single largest external validation, the 2026-08-05 approval, produced no new high. It still works — the three-month return is +40.5% — while the marginal buyer has thinned. It is not SATURATED yet because price has not given back the June breakout, and not ACCELERATING because the headline flow is now confirmatory rather than new.

Bullish and bearish views on Alkermes plc

The model's bull view on Alkermes plc (ALKS), in brief: 2026-08-05: FDA approval of Takeda's ORZEYFUL for NT1 removes mechanism risk from the entire OX2R class. The bear view: The Q3 guide of $450–470M sits below the $472.8M consensus (2026-07-28) — the first quantitative crack in the "commercial base compounds while the pipeline matures" leg. Both cases follow in full.

Bull Case

• 2026-08-05: FDA approval of Takeda's ORZEYFUL for NT1 removes mechanism risk from the entire OX2R class. The press release lists no boxed hepatic warning, only "avoid use in patients with severe hepatic impairment (Child-Pugh C)" — the read-through to the class liver overhang left by Takeda's halted TAK-994 is favourable.
• 2026-07-28: Q2 proprietary product sales $411.7M, +34% YoY, with LUMRYZ contributing $96.6M in its first full quarter post-acquisition; VIVITROL $124.5M, ARISTADA $96.7M, LYBALVI $94.0M (+12% YoY). The commercial base self-funds the orexin programme.
• 2026-07-13: interim long-term extension analysis showed alixorexton sustained clinically meaningful wakefulness gains — durability supported by data rather than a single acute readout.
• 2026-06-17: Vibrance-2 (NT2) met dual primary endpoints, the first large positive OX2R Phase 2 in narcolepsy type 2 — the segment Takeda's approved label does not cover.
• 2026-06-15: alixorexton received US orphan designation in idiopathic hypersomnia and EC orphan designation in narcolepsy.
• Pipeline optionality is dated: ALKS 7290 (ADHD) top-line "by end of third quarter", Vibrance-3 (IH) completion "fourth quarter", LUMRYZ sNDA for IH filed "by year-end", Phase 3 Brilliance completion expected in 2027 (Q2 call, 2026-07-28).
• Cash and investments ~$690M at quarter-end (2026-07-28 call).

Bear Case

• The Q3 guide of $450–470M sits below the $472.8M consensus (2026-07-28) — the first quantitative crack in the "commercial base compounds while the pipeline matures" leg.
• 2026-06-29: BofA's Jason Gerberry downgraded to Underperform with a $38 target after a 92% YTD rally, flagging VIVITROL loss of exclusivity in January 2027 and Takeda's TAK-360 Phase 2 in NT2/IH. Published targets now span $38 to $65 — a wide fair-value band that mechanically widens realized range.
• Takeda is first to market. ORZEYFUL availability follows DEA scheduling, "expected within 90 days" of 2026-08-05, i.e. roughly by early November; alixorexton's Phase 3 Brilliance studies do not complete until 2027.
• FY2026 GAAP net loss guidance was revised to $95–115M and EBITDA to $75–95M on a contingent-consideration charge (2026-07-28), even as product guidance was reaffirmed.
• The Avadel/LUMRYZ transaction added $1.525B of term loans due 2031 (~$775M cash deployed); deleveraging depends on the base holding its growth rate through the VIVITROL LOE step-down.
• No confirmed company-specific catalyst inside the next 30 days.

Setup & Price Structure

From a $25.17 52-week low the stock cleared its $45.76 prior high after Vibrance-2 on 2026-06-17, made a $55.22 52-week high, and has since worked back to a $49.17 close on 2026-08-07 — a 11.0% drawdown from the high with a three-month return still +40.5%. The momentum condition has fully unwound: RSI(14) at 39.3 versus readings in the 80s through June, without price surrendering the June breakout. The $45.76 prior-high shelf is the line that separates an orderly pullback inside the re-rate from a failed breakout.

Crowding and positioning observables, stated as observables: seven sell-side actions between 2026-06-09 and 2026-07-29, all but one raising targets, with the sole downgrade (BofA, 2026-06-29) already in the tape before the Q2 print; a target cluster at $58–$65 sitting 18–32% above the last close and a bear case at $38 sitting 23% below; a class-defining FDA approval on 2026-08-05 that did not produce a new high two sessions later; and no earnings binary in the near window, the Q2 print having cleared on 2026-07-28. Insider transaction data is not in evidence here and no claim is made about it either way.

Catalyst Calendar (next 30 days)

• ~2026-09-30 (est.) — ALKS 7290 (ADHD) Phase 1b top-line, guided "by end of third quarter" on the 2026-07-28 call. Falls just outside the 30-day window; the first non-orexin pipeline datapoint.
• ~2026-11-03 (est.) — DEA scheduling decision on ORZEYFUL, per Takeda's "expected within 90 days" of the 2026-08-05 approval. Gates the launch and therefore the first real-world orexin uptake data.
• ~2026-10-28 (est.) — Q3 2026 print, the check on whether the $450–470M guide was conservative or descriptive.
• By 2026-12-31 — LUMRYZ sNDA filing for idiopathic hypersomnia.

The honest read on the window: between 2026-08-09 and 2026-09-08 there is no confirmed dated company event. Anything that moves the name in that span is flow, class read-through from ORZEYFUL's launch mechanics, or a sell-side action.

Elapsed catalysts

• Q4 2026 — Vibrance-3 idiopathic hypersomnia Phase 2 completion (2026-07-28 call). The next genuine binary. (passed 12d ago)

What Would Change Our Mind

The structure that has to hold is the June breakout over $45.76. Losing it puts price back inside the pre-Vibrance-2 range and makes the entire orexin re-rate a round trip; the gradeable version of that is a weekly close below $44. On the fundamental side, three things would break the frame: Vibrance-3 missing in Q4 2026 (the IH indication is where alixorexton's differentiation versus an approved ORZEYFUL label actually lives), FY2026 revenue tracking to the $1.730B low end of the affirmed guide, or any hepatic signal emerging from the Phase 3 Brilliance studies. In the other direction, a weekly close above $55.22 on Vibrance-3 data would restore the accelerating condition and force this note's MATURING label to be revisited. If the stock is still below the $58–$65 target cluster after the Q4 readout has come and gone, the theme has flipped to SATURATED regardless of price.

Correlation Notes

• Takeda (4502.T) — ORZEYFUL launch metrics from the DEA scheduling date onward are the read on how large and how fast the NT1 orexin market is. Strong uptake validates the class and compresses the NT1 opportunity simultaneously.
• Centessa (CNTA) — ORX750/ORX142 datapoints move class sentiment on both directions; a competitor safety event is a theme-wide event.
• Jazz (JAZZ) — Xywav/Xyrem are LUMRYZ's direct competition; oxybate share commentary reads straight into the $350–370M LUMRYZ FY guide.
• Harmony Biosciences (HRMY) — pitolisant incumbency in narcolepsy; the orexin class is the structural threat to it, so the pair often trades inversely on class headlines.
• Small/mid-cap biotech beta (XBI) still governs the drawdown path when there is no company news, which describes the next 30 days.